Publications by authors named "Amy Halseth"

Claim this Profile
A
An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine.
Judy Caron, Randall Kaye, Thomas Wessel, Amy Halseth, Gary Kay

J Clin Pharm Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Anna I Guerdjikova, Brandon Walsh, Kevin Shan, Amy E Halseth, Eduardo Dunayevich

Adv Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Amy Halseth, Kevin Shan, Brandon Walsh, Kye Gilder, Ken Fujioka

Obesity (Silver Spring)· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Louis J Aronne, Amy E Halseth, Colleen M Burns, Stephan Miller, Larry Z Shen

Obesity (Silver Spring)· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Steve R Smith, Louis J Aronne, Colleen M Burns, Nicole C Kesty, Amy E Halseth

Diabetes Care· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
Louis Aronne, Ken Fujioka, Vanita Aroda, Kim Chen, Amy Halseth

J Clin Endocrinol Metab· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.
Steven R Smith, John E Blundell, Colleen Burns, Cinzia Ellero, Brock E Schroeder, Amy E Halseth

Am J Physiol Endocrinol Metab· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
Frauke Fehse, Michael Trautmann, Jens J Holst, Amy E Halseth, Nuwan Nanayakkara

J Clin Endocrinol Metab· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of PYK2 in the development of obesity and insulin resistance.
Ying Yu, Stuart A Ross, Amy E Halseth, Paul W Hollenbach, Ronald J Hill

Biochem Biophys Res Commun· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fiber type-specific determinants of Vmax for insulin-stimulated muscle glucose uptake in vivo.
Hilary Ann Petersen, Patrick T Fueger, Deanna P Bracy, David H Wasserman, Amy E Halseth

Am J Physiol Endocrinol Metab· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.
Amy E Halseth, Nancy J Ensor, Tommi A White, Stuart A Ross, Eric A Gulve

Biochem Biophys Res Commun· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis